Michael D Ellis1, Ingrid Schut2, Julius P A Dewald3. 1. Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: m-ellis@northwestern.edu. 2. Faculty of Science and Technology, University of Twente, Enschede, Netherlands. 3. Department of Physical Therapy and Human Movement Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Biomedical Engineering, McCormick School of Engineering, Northwestern University, Chicago, IL, USA; Department of Physical Medicine and Rehabilitation, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Faculty of Science and Technology, University of Twente, Enschede, Netherlands.
Abstract
OBJECTIVE: Pharmaceutical intervention targets arm flexor spasticity with an often-unsuccessful goal of improving function. Flexion synergy is a related motor impairment that may be inadvertently neglected. Here, flexor spasticity and flexion synergy are disentangled to determine their contributions to reaching dysfunction. METHODS: Twenty-six individuals participated. A robotic device systematically modulated shoulder abduction loading during ballistic reaching. Elbow muscle electromyography data were partitioned into windows delineated by elbow joint velocity allowing for the separation of synergy- and spasticity-related activation. RESULTS: Reaching velocity decreased with abduction loading (p<0.001) such that velocity was 30% slower when lifting the arm at 50% of abduction strength compared to when arm weight was supported. Abnormal flexion synergy increased with abduction loading (p<0.001) such that normalized activation ranged from a median (interquartile range) of 0.07 (0.03-0.12) when arm weight was supported to 0.19 (0.12-0.40) when actively lifting (large effect size, d=0.59). Flexor spasticity was detected during reaching (p=0.016) but only when arm weight was supported (intermediate effect size, d=0.33). CONCLUSION: Flexion synergy is the predominant contributor to reaching dysfunction while flexor spasticity appears only relevant during unnaturally occurring passively supported movement. SIGNIFICANCE: Interventions targeting flexion synergy should be leveraged in future stroke recovery trials.
OBJECTIVE: Pharmaceutical intervention targets arm flexor spasticity with an often-unsuccessful goal of improving function. Flexion synergy is a related motor impairment that may be inadvertently neglected. Here, flexor spasticity and flexion synergy are disentangled to determine their contributions to reaching dysfunction. METHODS: Twenty-six individuals participated. A robotic device systematically modulated shoulder abduction loading during ballistic reaching. Elbow muscle electromyography data were partitioned into windows delineated by elbow joint velocity allowing for the separation of synergy- and spasticity-related activation. RESULTS: Reaching velocity decreased with abduction loading (p<0.001) such that velocity was 30% slower when lifting the arm at 50% of abduction strength compared to when arm weight was supported. Abnormal flexion synergy increased with abduction loading (p<0.001) such that normalized activation ranged from a median (interquartile range) of 0.07 (0.03-0.12) when arm weight was supported to 0.19 (0.12-0.40) when actively lifting (large effect size, d=0.59). Flexor spasticity was detected during reaching (p=0.016) but only when arm weight was supported (intermediate effect size, d=0.33). CONCLUSION:Flexion synergy is the predominant contributor to reaching dysfunction while flexor spasticity appears only relevant during unnaturally occurring passively supported movement. SIGNIFICANCE: Interventions targeting flexion synergy should be leveraged in future stroke recovery trials.
Authors: Cláudia C Silva; Augusta Silva; Andreia Sousa; Ana Rita Pinheiro; Catarina Bourlinova; Ana Silva; António Salazar; Carla Borges; Carlos Crasto; Miguel Velhote Correia; João Paulo Vilas-Boas; Rubim Santos Journal: J Electromyogr Kinesiol Date: 2014-05-09 Impact factor: 2.368
Authors: Michael D Ellis; Justin Drogos; Carolina Carmona; Thierry Keller; Julius P A Dewald Journal: J Neurophysiol Date: 2012-09-05 Impact factor: 2.714
Authors: Emily M Mugler; Goran Tomic; Aparna Singh; Saad Hameed; Eric W Lindberg; Jon Gaide; Murad Alqadi; Elizabeth Robinson; Katherine Dalzotto; Camila Limoli; Tyler Jacobson; Jungwha Lee; Marc W Slutzky Journal: Neurorehabil Neural Repair Date: 2019-03-19 Impact factor: 3.919
Authors: Yuan Yang; Nirvik Sinha; Runfeng Tian; Netta Gurari; Justin M Drogos; Julius P A Dewald Journal: IEEE Trans Neural Syst Rehabil Eng Date: 2020-04-07 Impact factor: 3.802
Authors: Keith D Runnalls; Pablo Ortega-Auriol; Angus J C McMorland; Greg Anson; Winston D Byblow Journal: Exp Brain Res Date: 2019-11-14 Impact factor: 1.972
Authors: Na Jin Seo; Alex Barry; Mohammad Ghassemi; Kristen M Triandafilou; Mary Ellen Stoykov; Lynn Vidakovic; Elliot Roth; Derek G Kamper Journal: J Neurol Phys Ther Date: 2022-03-22 Impact factor: 4.655